Signal transduction proteins in tumors from puerto rican and caucasian gastric adenocarcinoma patients: Expression differences with potential for specific targeted therapies

Digestive Diseases and Sciences

Volumn 53, Issue 8, 2008, Pages 2090-2100

  Cangiano, José ^a   Centeno, Barbara A ^b,c   Garrett, Christopher R ^b,c   Cáceres, William ^d   De Jesús, Ana ^d   Lee, Ji Hyun ^b,c   Pavía, Orestes ^e   Jove, Richard ^f   Báez, Luis ^d   Sullivan, Daniel M ^b,c   Muro Cacho, Carlos A ^g   Muñoz Antonia, Teresita ^b  

^a PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d VA MEDICAL CENTER   (Puerto Rico)

^e Auxilio Mutuo Hospital   (Puerto Rico)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclin D1; Epidermal growth factor receptor; Gastric adenocarcinoma; Her2 neu; Stat3; Stomach cancer

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; STAT3 PROTEIN;

ADULT; ARTICLE; CANCER PATIENT; CAUCASIAN; COMPARATIVE STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUERTO RICO; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, SIGNET RING CELL; CYCLINS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FLORIDA; HISPANIC AMERICANS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PATIENT SELECTION; PUERTO RICO; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS;

EID: 46449087606     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-0118-5     Document Type: Article

References (59)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8-29
2. Bosetti C, Malvezzi M, Chatenoud L, Negri E, Levi F, La Vecchia C (2005) Trends in cancer mortality in the Americas, 1970-2000. Ann Oncol 16:489-511
3. Ramirez RR (2004) We the people: Hispanics in the United States, census 2000 special reports. US Census Bureau, Washington, DC
4. Rosenwaike I, Shai D (1986) Trends in cancer mortality among Puerto Rican-born migrants to New York City. Int J Epidemiol 15:30-35
5. Menendez-Bergad B, Blum S (1989) Stomach cancer in a native and migrant population in Puerto Rico and New York City, 1975-1979. Bol Asoc Med P R 81:95-98
6. Monk M, Warshauer ME (1975) Stomach and colon cancer mortality among Puerto Ricans in New York City and Puerto Rico. J Chronic Dis 28:349-358
7. Warshauer ME, Silverman DT, Schottenfeld D, Pollack ES (1986) Stomach and colorectal cancers in Puerto Rican-born residents of New York City. J Natl Cancer Inst 76:591-595
8. Lores ME, Sorrentino R, Vallecillo L, Rossello PJ (1980) Carcinoma of the stomach: experience at the University Hospital. Bol Asoc Med P R 72:290-297
9. Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, Schnirer II, Reddy S, Chiang SS, Najam A, Yu C, Giacco GG, Xie K, Wu TT, Feig BW, Pisters PW, Ajani JA (2005) Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol 23:3094-3103
10. Yao JC, Schnirer II, Reddy S, Chiang S, Najam A, Yu C, Giacco G, Hess K, Rashid A, Xie K, Lynch P, Ajani JA (2002) Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer 5:208-212
11. Cullinan SA, Moertel CG, Wieand HS, O'Connell MJ, Poon MA, Krook JE, Mailliard JA, Tschetter LK (1994) Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol 12:412-416
12. Hinoda Y, Sasaki S, Ishida T, Imai K (2004) Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer Sci 95:621-625
13. Yoshida T, Sakamoto H, Terada M (1993) Amplified genes in cancer in upper digestive tract. Semin Cancer Biol 4:33-40
14. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B (2005) EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 18:1027-1033
15. Ross JS, McKenna BJ (2001) The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 19:554-568
16. Vizoso FJ, Corte MD, Alvarez A, Garcia I, del Casar JM, Bongera M, Gonzalez LO, Garcia-Muniz JL, Allende MT (2004) Membranous levels of c-erbB-2 oncoprotein in gastric cancer: their relationship with clinicopathological parameters and their prognostic significance. Int J Biol Markers 19:268-274
17. Kono K, Naganuma H, Sekikawa T, Amemiya H, Takahashi A, Iizuka H, Matsumoto Y (2000) Serum level of HER-2/neu in patients with gastric cancer: correlation with HER-2/neu overexpression in gastric carcinoma tissue. Tumour Biol 21:139-144
18. Oshima CT, Lanzoni VP, Iriya K, Forones NM (2001) C-erbB-2 oncoprotein in gastric carcinoma: correlation with clinical stage and prognosis. Int J Biol Markers 16:250-254
19. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J (2005) Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16:273-278
20. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM (2000) c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 18:2201-2209
21. Sanz-Ortega J, Steinberg SM, Moro E, Saez M, Lopez JA, Sierra E, Sanz-Esponera J, Merino MJ (2000) Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer. Histol Histopathol 15:455-462
22. Shida D, Kitayama J, Yamaguchi H, Yamashita H, Mori K, Watanabe T, Nagawa H (2005) Lysophospholipids transactivate HER2/neu (erbB-2) in human gastric cancer cells. Biochem Biophys Res Commun 327:907-914
23. Kimura M, Tsuda H, Morita D, Shinto E, Tanimoto T, Ichikura T, Mochizuki H, Matsubara O (2005) Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma. Jpn J Clin Oncol 35:324-331
24. Garcia I, Vizoso F, Andicoechea A, Fernandez P, Suarez C, Garcia-Munz JL, Allende MT (2000) C-erbB-2 oncoprotein content in gastric cancer and in adjacent mucosa. Int J Biol Markers 15:231-234
25. Ougolkov A, Mai M, Takahashi Y, Omote K, Bilim V, Shimizu A, Minamoto T (2000) Altered expression of beta-catenin and c-erbB-2 in early gastric cancer. J Exp Clin Cancer Res 19:349-355
26. Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, Eweis I, Wloch M, Livingston S, Seijo E, Cantor A, Lee J-H, Beam CA, Sullivan D, Jove R, Muro-Cacho C (2006) Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated Src and survivin expression. Clin Cancer Res 12:20-28
27. Moiseyenko VM, Ajani JA, Tjulandin SA, Majlis A, Constenla M, Boni C, Anelli A, Yver AJ, Van Cutsem E (2005) Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC) [on behalf of the TAX 325 Study Group]. In: Proceedings of the 2005 ASCO annual meeting, Orlando, FL, USA
28. Kubo A, Corley DA (2004) Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States. Am J Gastroenterol 99:582-588
29. El-Serag HB, Sonnenberg A (1999) Ethnic variations in the occurrence of gastroesophageal cancers. J Clin Gastroenterol 28:135-139
30. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G Jr, Winchester D, Osteen R (1993) Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 218:583-592
31. Correa P (1985) Clinical implications of recent developments in gastric cancer pathology and epidemiology. Semin Oncol 12:2-10
32. Schwarz RE, Zagala-Nevarez K (2002) Ethnic survival differences after gastrectomy for gastric cancer are better explained by factors specific for disease location and individual patient comorbidity. Eur J Surg Oncol 28:214-219
33. Nishigaki R, Osaki M, Hiratsuka M, Toda T, Murakami K, Jeang KT, Ito H, Inoue T, Oshimura M (2005) Proteomic identification of differentially-expressed genes in human gastric carcinomas. Proteomics 5:3205-3213
34. Kountouras J, Zavos C, Chatzopoulos D (2005) New concepts of molecular biology on gastric carcinogenesis. Hepatogastroenterology 52:1305-1312
35. Keller G, Hofler H, Becker KF (2005) Molecular medicine of gastric adenocarcinomas. Expert Rev Mol Med 7:1-13
36. De Luca A, Iaquinto G (2004) Helicobacter pylori and gastric diseases: a dangerous association. Cancer Lett 213:1-10
37. Scartozzi M, Galizia E, Freddari F, Berardi R, Cellerino R, Cascinu S (2004) Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev 30:451-459
38. Myllykangas S, Monni O, Nagy B, Rautelin H, Knuutila S (2004) Helicobacter pylori infection activates FOS and stress-response genes and alters expression of genes in gastric cancer-specific loci. Genes Chromosomes Cancer 40:334-341
39. Wang J, Chi DS, Kalin GB, Sosinski C, Miller LE, Burja I, Thomas E (2002) Helicobacter pylori infection and oncogene expressions in gastric carcinoma and its precursor lesions. Dig Dis Sci 47:107-113
40. Schneider BG, Hilsenbeck SG, Hensel CH, Pekkel V, Shelton CH, Rodriguez-Martinez HA, Gutierrez-Diaz ME, Pulitzer DR, Allred DC (1994) p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos. Virchows Arch 424:187-193
41. Morales TG, Sampliner RE, Camargo E, Marquis S, Garewal HS, Fennerty MB (2001) Inability to noninvasively diagnose gastric intestinal metaplasia in Hispanics or reverse the lesion with Helicobacter pylori eradication. J Clin Gastroenterol 32:400-404
42. Alexander GA, Brawley OW (2000) Association of Helicobacter pylori infection with gastric cancer. Mil Med 165:21-27
43. Cangiano JA, Muro-Cacho C, Antonia T, Caceres W, Pavia O, Baez L (2003) Overexpression of the HER2/NEU gene in human gastric adenocarcinoma in Hispanics. In: Proceedings of the American Society of Clinical Oncology, 22:A-3457
44. Kimura M, Tsuda H, Morita D, Ichikura T, Ogata S, Aida S, Yoshizumi Y, Maehara T, Mochizuki H, Matsubara O (2004) A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Arch 445:255-262
45. Varis A, Zaika A, Puolakkainen P, Nagy B, Madrigal I, Kokkola A, Vayrynen A, Karkkainen P, Moskaluk C, El-Rifai W, Knuutila S (2004) Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int J Cancer 109:548-553
46. Funato T, Kozawa K, Fujimaki S, Miura T, Kaku M (2001) Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the her-2/neu (c-erbB-2) gene. Chemotherapy 47:297-303
47. Risio M, De Rosa G, Sarotto I, Casorzo L, Capussotti L, Torchio B, Aglietta M, Chiecchio L (2003) HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples. Int J Oncol 23:1381-1387
48. Mizutani T, Onda M, Tokunaga A, Yamanaka N, Sugisaki Y (1993) Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 72:2083-2088
49. Tsugawa K, Yonemura Y, Hirono Y, Fushida S, Kaji M, Miwa K, Miyazaki I, Yamamoto H (1998) Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology 55:475-481
50. Gurel S, Dolar E, Yerci O, Samli B, Ozturk H, Nak SG, Gulten M, Memik F (1999) The relationship between c-erbB-2 oncogene expression and clinicopathological factors in gastric cancer. J Int Med Res 27:74-78
51. Bi F, Fan D, Hui H, Wang C, Zhang X (2001) Reversion of the malignant phenotype of gastric cancer cell SGC7901 by c-erbB-2-specific hammerhead ribozyme. Cancer Gene Ther 8:835-842
52. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y (2007) Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 59:795-805
53. Gong SJ, Jin CJ, Rha SY, Chung HC (2004) Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett 214:215-224
54. Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A (2006) Topoisomerase II alpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum Pathol 37:1333-1343
55. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, Son BH, Cho EY, Chae SW, Kim EJ, Sohn JH, Ryu SH, Sepulveda AR (2006) HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51:1371-1379
56. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, Ochiai A (2006) Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15:65-71
57. Bizari L, Borim AA, Leite KR, Goncalves FT, Cury PM, Tajara EH, Silva AE (2006) Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. Cancer Genet Cytogenet 165:41-50
58. Garcia I, del Casar JM, Corte MD, Allende MT, Garcia-Muniz JL, Vizoso F (2003) Epidermal growth factor receptor and c-erbB-2 contents in unresectable (UICC R1 or R2) gastric cancer. Int J Biol Markers 18:200-206
59. Takehana T, Kunitomo K, Suzuki S, Kono K, Fujii H, Matsumoto Y, Ooi A (2003) Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol 1:438-445